Infliximab for intravenous immunoglobulin-resistant Kawasaki disease complicated with cholestatic hepatitis: a case report and discussion on coronary artery aneurysm prevention. [PDF]
Front PediatrYongxing Z, Zheng Z, Qi Z, Fangyan Y.
europepmc +1 more source
Impact of Proactive Therapeutic Drug Monitoring on Infliximab Maintenance Therapy and Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Randomized Controlled Trial and Review of Literature. [PDF]
Gastro Hep AdvCares K +4 more
europepmc +1 more source
Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial. [PDF]
Adv TherSchreiber S +7 more
europepmc +1 more source
The GETAID: over 40 years of academic research in IBD. [PDF]
Ther Adv GastroenterolLaharie D +4 more
europepmc +1 more source
Patient out-of-pocket costs and rheumatology biosimilar competition. [PDF]
J Manag Care Spec PharmDayer VW +4 more
europepmc +1 more source
Biologic Therapy in Ulcerative Colitis: A Retrospective Real-World Study in a Brazilian Tertiary University Hospital. [PDF]
CureusVarandas HM, Varandas ACM, Clemente CM.
europepmc +1 more source
Short-term efficacy and safety of infliximab biosimilar (HS626) in inducing remission of inflammatory bowel disease: A real-world single-center study. [PDF]
Medicine (Baltimore)Huang YS +7 more
europepmc +1 more source
Biosimilars in Adult and Pediatric Noninfectious Uveitis. [PDF]
Clin OphthalmolPloeger CG +3 more
europepmc +1 more source
Pharmacovigilance analysis of infliximab in inflammatory bowel disease: novel safety signals and sex-specific adverse event profiles from the FAERS database (2004-2024). [PDF]
Front ImmunolLiu W +6 more
europepmc +1 more source
Clinical evidence and implementation guidance for biosimilar switching in ankylosing spondylitis. [PDF]
Front PharmacolCai L +6 more
europepmc +1 more source